Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers

The first gene therapy product, recombinant adenovirus human p53 (rAd-p53), has been approved by CFDA since 2013. During these years, most of the clinical trials and the relevant basic research were carried out by Chinese oncologists. Gendicine was proved to be a safe and promising gene therapy drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yi, Guo, Wei, Li, Xiuqin, Zhang, Jianguo, Sun, Moyi, Tang, Zhangui, Ran, Wei, Yang, Kai, Huang, Guilin, Li, Longjiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595718/
https://www.ncbi.nlm.nih.gov/pubmed/34785635
http://dx.doi.org/10.1038/s41368-021-00145-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595718/
https://www.ncbi.nlm.nih.gov/pubmed/34785635
http://dx.doi.org/10.1038/s41368-021-00145-1

Ejemplares similares